| 2.16 -0.01 (-0.46%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.6 | 1-year : | 3.04 |
| Resists | First : | 2.23 | Second : | 2.6 |
| Pivot price | 2.12  |
|||
| Supports | First : | 2 | Second : | 1.87 |
| MAs | MA(5) : | 2.16 |
MA(20) : | 2.1 |
| MA(100) : | 2.32 |
MA(250) : | 2.85 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 76.8 |
D(3) : | 77.4 |
| RSI | RSI(14): 51.9 |
|||
| 52-week | High : | 4.88 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BMRA ] has closed below upper band by 34.4%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.16 - 2.17 | 2.17 - 2.18 |
| Low: | 2.04 - 2.05 | 2.05 - 2.06 |
| Close: | 2.14 - 2.16 | 2.16 - 2.18 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Wed, 18 Mar 2026
Biomerica Secures First Commercial Order for Hp Detect™ from Major European Laboratory Chain - Quiver Quantitative
Wed, 18 Mar 2026
Stomach cancer bacteria drives major lab’s first order of Hp Detect test - Stock Titan
Thu, 26 Feb 2026
Biomerica, Inc. Reports Successful Responder Analysis Results for inFoods® IBS and Establishes $300 Medicare Payment Rate - Quiver Quantitative
Thu, 26 Feb 2026
New finger-stick IBS test eases pain and bloating for most patients - Stock Titan
Thu, 26 Jun 2025
Biomerica Inc. Appoints Scott Madel as Chief Commercial Officer to Drive Growth of inFoods® IBS - Quiver Quantitative
Sun, 31 Mar 2024
symbol__ Stock Quote Price and Forecast - cnn.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 72 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.5 |
| Profit Margin | -90.4 % |
| Operating Margin | -113.5 % |
| Return on Assets (ttm) | -49.5 % |
| Return on Equity (ttm) | -84.4 % |
| Qtrly Rev. Growth | -26 % |
| Gross Profit (p.s.) | 0.08 |
| Sales Per Share | 1.47 |
| EBITDA (p.s.) | -1.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.87 |
| PEG Ratio | 0 |
| Price to Book value | 1.44 |
| Price to Sales | 1.46 |
| Price to Cash Flow | -2.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|